Adagio Medical Holdings, Inc.ADGMEarnings & Financial Report
Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing innovative cryoablation platforms for treating cardiac arrhythmias, most notably atrial fibrillation. Its solutions are designed for electrophysiology clinicians, with primary commercial operations across North America and Europe, focused on improving safety and outcomes for patients living with heart rhythm disorders.
ADGM Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-5.7M
Net Profit
$-10.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.66
Adagio Medical Holdings, Inc. Q3 FY2025 Financial Summary
Adagio Medical Holdings, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-10.1M (down 380.6% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-10.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Adagio Medical Holdings, Inc. Quarterly Revenue & Net Profit History
Adagio Medical Holdings, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-10.1M | N/A |
| Q3 FY2024 | $132.0K | — | $3.6M | 2731.8% |
| Q2 FY2024 | $254.0K | — | $-5.7M | -2257.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|
| Revenue | $254000 | $132000 | $0 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|
| Assets | $-140.5M | $107.2M | $31.5M |
| Liabilities | $5000 | $30.6M | $32.9M |
| Equity | $-140.5M | $76.6M | $-1.3M |
Cash Flow
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-6.4M | $-3.0M |